Cancer Clinical Trials: In-Depth Information

Similar documents
Cancer Clinical Trials: The Basics

Clinical Trials: Questions and Answers

Cancer Clinical Trials

Cancer Clinical Trials

TAKING PART IN CANCER TREATMENT RESEARCH STUDIES

National Cancer Institute

Clinical Trials: What You Need to Know

Ask Us About Clinical Trials

What Cancer Patients Need To Know

The NCI/VA Agreement on Clinical Trials: Questions and Answers. Key Points

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective

LUNG CANCER CLINICAL TRIALS

Navigating GIST. The Life Raft Group June 12, 2008

Clinical Trials: What You Need to Know

Clinical Trials: The Crux of Cancer Innovation

Glossary of Clinical Trial Terms

Introduction to Data Auditing

A guide for the patient

The Clinical Trials Process an educated patient s guide

A Greater Understanding. A Practical Guide to Clinical Trials

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Understanding the Clinical Research Process and Principles of Clinical Research

Clinical Trials: Improving the Care of People Living With Cancer

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

Guidance for Industry

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Guidance for Industry

Update in Hematology Oncology Targeted Therapies. Mark Holguin

A Letter from MabVax Therapeutics President and Chief Executive Officer

Josephine Silvestre, RN, MSN The University of Chicago Medical Center. October 13, 2007

Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations

Regulatory Issues in Genetic Testing and Targeted Drug Development

Clinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group

Participating in Alzheimer s Disease Clinical Trials and Studies

Clinical Trials and Screening: What You Need to Know

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment Chapter3 ValueandSpending...

Guidance for Industry

Avastin in Metastatic Breast Cancer

Understanding Clinical Trials for Blood Cancers. Blood Cancer Treatment Series

Medicare Billing. Lisa R. Pitler, JD, MS, RN Assistant Vice Chancellor Research, Director of Clinical Trials Office University of Illinois at Chicago

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

Your Immune System & Lung Cancer Treatment

Report series: General cancer information

Statement for the Record for the September 25, 2008, hearing entitled, Cell Phone Use and Tumors: What the Science Says

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental

AAHRPP DOCUMENT # 84 UNIVERSITY OF ALABAMA HUMAN RESEARCH PROTECTIONS PROGRAM FORM: NOTIFICATION TO IRB OF EMERGENCY USE OF A TEST ARTICLE

Principal Investigator and Sub Investigator Responsibilities

Expanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical

Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

Accelerating Development and Approval of Targeted Cancer Therapies

EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND

National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry

Future Directions in Cancer Research What does is mean for medical physicists and AAPM?

Entering a Clinical Trial

Lighting The Way. A practical guide to Clinical Trials

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions

Butler Memorial Hospital Community Health Needs Assessment 2013

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS

Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs

Cancer Association of South Africa (CANSA)

Patient Handbook on Stem Cell Therapies

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt

Nuevas tecnologías basadas en biomarcadores para oncología

Roles & Responsibilities of the Sponsor

Lymphoma. Starting Point. Diagnosed with Lymphoma?

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

Human Subjects Research (HSR) Series

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Electronic health records to study population health: opportunities and challenges

Title: Department: Approved by:

Transcription:

Cancer Clinical Trials: In-Depth Information

The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3) 4. NDA filed with FDA 5. FDA validates claim and approves drug 2

Phases of Clinical Trials Phase 1: 15-30 people What dosage is safe? How should treatment be given? How does treatment affect the body? Phase 2: Less than 100 people Does treatment do what it is supposed to? How does treatment affect the body? 3

Phases of Clinical Trials Phase 3: From 100 to thousands of people Compare new treatment with current standard Phase 4: From hundreds to thousands of people Usually takes place after drug is approved Used to further evaluate long-term safety and effectiveness of new treatment 4

Types of Clinical Trials Treatment Prevention Screening and early detection Diagnostic Genetics Quality-of-life / supportive care 5

Treatment Trials Test safety and effectiveness of new agents or interventions in people with cancer Possible benefit: Early access to new treatments Possible risk: Occurrence of unknown side effects 6

Prevention Trials For people at risk of developing cancer Action studies vs. agent studies Possible benefit: Early access to new interventions Possible risk: Unknown side effects and effectiveness 7

Screening and Early-Detection Trials Assess new means of detecting cancer earlier in healthy people Possible benefit: Detecting disease at an earlier stage, resulting in improved outcomes Possible risks: Discomfort and inconvenience If imaging technique is studied, exposure to x- rays or radioactive substances 8

Diagnostic Trials Develop better tools for classifying types and phases of cancer and managing patient care Possible benefits: New technology may be better and less invasive Earlier detection of recurrences Possible risk: May require people to take multiple tests 9

These trials seek to: Genetics Trials Determine how one s genetic makeup can influence detection, diagnosis, prognosis, and treatment Broaden understanding of causes of cancer Develop targeted treatments based on the genetics of a tumor 10

Quality-of-Life / Supportive Care Trials Aim to improve quality of life for patients and their families Possible benefit: Early access to new treatment Possible risk: May not benefit from participation 11

Clinical Trial Protocol A written, detailed action plan that: Provides background about the trial Specifies trial objectives Describes trial s design and organization Ensures that trial procedures are consistently carried out 12

Investigational Drug Use Outside of a Clinical Trial Group C drugs Treatment Investigational New Drug application Compassionate use program 13

Clinical Trial Design Eligibility criteria: Can range from general (age, sex, type of cancer) to specific (prior treatment, tumor characteristics, blood cell counts, organ function); eligibility criteria also vary with trial phase Varies with protocol and phases Endpoint: Measurable outcome that indicates an intervention s effectiveness 14

Clinical Trial Design Randomization: A method used to prevent bias in research; a computer or a table of random numbers generates treatment assignments, and participants have an equal chance to be assigned to one of two or more groups (e.g., the control group or the investigational group) 15

Randomization 16

Clinical Trial Design Stratification: Categorizing subjects into subgroups by specific characteristics Enables researchers to look into separate subgroups to see whether differences exist 17

Stratification 18

The Final Step: FDA Approval Review of New Drug Application (NDA) or Biologics License Application (BLA) Labeling Continued monitoring Feedback 19

Releasing the Results of Clinical Trials Peer-reviewed journals Public announcements Results not made public until end of trial 20

Improving Cancer Prevention, Detection, and Treatment Once proven safe and effective in a clinical trial, an intervention may become the new standard of care 21

Advancing Cancer Care Gleevec for chronic myelogenous leukemia Cervical cancer: improved survival rates Breast cancer: less extensive surgery Intron-A for melanoma Biological therapy Monoclonal antibodies Cancer vaccines 22

Evolution of Participant Protection Nuremberg Tuskegee Syphilis Study National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research Belmont Report National Research Act 23

Government Oversight of Safeguards for Participants Office for Human Research Protections (OHRP) The Common Rule FDA Regulations 24

Protecting Participants Before a Trial Scientific review by sponsoring organization Institutional review board approval Informed consent 25

Protecting Participants During a Clinical Trial Institutional review boards (IRBs) Data and safety monitoring boards (DSMBs) Minimize risks Ensure integrity of data Can stop study if necessary 26

Barriers to, Benefits of, and Risks of Participation in Clinical Trials

Barriers to Adult Participation in Clinical Trials Physicians and other health professionals may: Be unaware of appropriate trials Be unwilling to lose control of patient s care Believe that standard therapy is best Believe that clinical trials are more work Harbor concerns about the patient s care or how the person will react to suggestion of clinical trial participation 28

Barriers to Adult Participation in Clinical Trials Patients may: Be unaware of clinical trials Lack access to trials Fear, distrust, or be suspicious of research Have practical or personal obstacles Face insurance or cost problems Be unwilling to go against their physicians wishes 29

Benefits of Participating in Clinical Trials Early access to new treatments Active role in own health care Participation in advancing medical knowledge 30

Risks of Participating in Clinical Trials New treatments are not always better than standard care Unexpected side effects May not work for everyone Additional cost 31

NCI-Sponsored Clinical Trial Programs Clinical Trials Cooperative Group Program Clinical Trials Support Unit (CTSU) Community Clinical Oncology Program (CCOP) Minority-Based Community Clinical Oncology Program Cancer Centers Program Clinical Grants Program 32

Referring Patients to Clinical Trials Health care professionals should know: Trial objectives Eligibility criteria Treatment and prevention options 33

Locating NCI Clinical Trials in the Community NCI clinical trial registry: Nation s most comprehensive resource on cancer clinical trials www.cancer.gov 1-800-4-CANCER (1-800-422-6237) 34